Health-related quality of life in men with prostate cancer undergoing active surveillance versus radical prostatectomy, external-beam radiotherapy, prostate brachytherapy and reference population

The purpose of this study is to describe Health-Related Quality of Life (HRQoL) of localized prostate cancer patients in an Active Surveillance (AS) program, and to compare them with those undergoing radical prostatectomy (RP), external-beam radiotherapy (XRT) and brachytherapy (BT). Multi-instituti...

Descripción completa

Detalles Bibliográficos
Autores: Sureda, A., Fumadó, Lluís|||0000-0003-3996-167X, Ferrer Forés, Maria Montserrat|||0000-0001-9867-7391, Garin, Olatz|||0000-0001-6193-0779, Bonet, Xavier, Castells-Esteve, Manel|||0000-0003-2370-2008, Mir, M. C., Abascal, Jose Maria|||0000-0001-8374-6593, Vigués, Francesc|||0000-0003-3717-6301, Cecchini, Lluís|||0000-0002-8873-0969, Suárez, J. F.
Tipo de recurso: artículo
Fecha de publicación:2019
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:226310
Acceso en línea:https://ddd.uab.cat/record/226310
https://dx.doi.org/urn:doi:10.1186/s12955-019-1082-4
Access Level:acceso abierto
Palabra clave:Active surveillance
Brachytherapy
External-beam radiotherapy
Health-related quality of life
Radical prostatectomy
Descripción
Sumario:The purpose of this study is to describe Health-Related Quality of Life (HRQoL) of localized prostate cancer patients in an Active Surveillance (AS) program, and to compare them with those undergoing radical prostatectomy (RP), external-beam radiotherapy (XRT) and brachytherapy (BT). Multi-institutional pooled cross-sectional analysis on patients in an AS protocol: 75 years old; pathologically confirmed LPC (maximum of three positive cylinders); Gleason score 3 + 4; clinical stage T1a-T2b; and PSA < 15 ng/ml. Exclusion criteria for this study were: less than 6 months in AS, termination of AS protocol, or incomplete data. Patients in AS were matched with those treated with RP, XRT or BT from the 'Spanish Multicentric Study of Clinically Localized Prostate Cancer' cohort according to risk group, time from treatment selection to HRQoL survey, and age. Prostate-specific (EPIC) and generic (SF-36) HRQoL instruments were completed. Analysis was stratified by HRQoL survey moment (.

Similares en LA Referencia